Low-carbohydrate, high-protein diets may reduce both tumor growth rates and cancer risk

Eating a low-carbohydrate, high-protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

The study was conducted in mice, but the scientists involved agree that the strong biological findings are definitive enough that an effect in humans can be considered.

"This shows that something as simple as a change in diet can have an impact on ," said lead researcher Gerald Krystal, Ph.D., a distinguished scientist at the British Columbia Cancer Research Centre.

Cancer Research editor-in-chief George Prendergast, Ph.D., CEO of the Lankenau Institute for Medical Research, agreed. "Many are interested in making changes in areas that they can control, and this study definitely lends credence to the idea that a change in diet can be beneficial," said Prendergast, who was not involved with the study.

Krystal and his colleagues implanted various of mice with human tumor cells or with mouse tumor cells and assigned them to one of two diets. The first diet, a typical , contained about 55 percent carbohydrate, 23 percent protein and 22 percent fat. The second, which is somewhat like a South Beach diet but higher in protein, contained 15 percent carbohydrate, 58 percent protein and 26 percent fat. They found that the tumor cells grew consistently slower on the second diet.

As well, mice genetically predisposed to were put on these two diets and almost half of them on the Western diet developed breast cancer within their first year of life while none on the low-carbohydrate, high-protein diet did. Interestingly, only one on the Western diet reached a normal life span (approximately 2 years), with 70 percent of them dying from cancer while only 30 percent of those on the developed cancer and more than half these mice reached or exceeded their normal .

Krystal and colleagues also tested the effect of an mTOR inhibitor, which inhibits cell growth, and a COX-2 inhibitor, which reduces inflammation, on tumor development, and found these agents had an additive effect in the mice fed the low-carbohydrate, high-protein diet.

When asked to speculate on the biological mechanism, Krystal said that tumor cells, unlike normal cells, need significantly more glucose to grow and thrive. Restricting carbohydrate intake can significantly limit blood glucose and insulin, a hormone that has been shown in many independent studies to promote tumor growth in both humans and mice.

Furthermore, a low-carbohydrate, has the potential to both boost the ability of the immune system to kill cancer cells and prevent obesity, which leads to chronic inflammation and cancer.

Related Stories

A low-carb diet may stunt prostate tumor growth

Nov 13, 2007

A diet low in carbohydrates may help stunt the growth of prostate tumors, according to a new study led by Duke Prostate Center researchers. The study, in mice, suggests that a reduction in insulin production possibly caused ...

Recommended for you

New breast cancer imaging method promising

40 minutes ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

1 hour ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

Breast cancer replicates brain development process

1 hour ago

New research led by a scientist at the University of York reveals that a process that forms a key element in the development of the nervous system may also play a pivotal role in the spread of breast cancer.

Is genetic instability the key to beating cancer?

3 hours ago

Cancerous tumors may be poised at the edge of their own destruction, an insight that could help researchers find new, more effective treatments, suggest SFI External Professor Ricard Solé and colleagues in an April 9 paper ...

Phase 3 study may be game-changer for acute myeloid leukemia

6 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments